Anti-Coagulants - Burundi

Burundi

The Anti-Coagulants market in Burundi is expected to witness significant revenue growth in the coming years.
By 2024, the revenue is projected to reach US$0.55m.
Furthermore, the market is anticipated to maintain a steady annual growth rate of 8.58% from 2024 to 2029.
This growth will lead to a market volume of US$0.83m by 2029.
When comparing the global market, it is worth noting that United States will generate the highest revenue.
In 2024 alone, United States is expected to generate a substantial revenue of US$16,740.00m.
In Burundi, the demand for anti-coagulants is on the rise due to an aging population and an increase in cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Coagulants in Burundi has been increasing steadily in recent years.

Customer preferences: The Burundian population has a growing awareness of health issues and has been increasingly seeking medical attention and treatment. This has led to an increase in the demand for Anti-Coagulants as a treatment for various cardiovascular diseases.

Trends in the market: The Anti-Coagulants market in Burundi has been witnessing a shift towards the use of newer oral Anti-Coagulants. The market has been dominated by traditional Anti-Coagulants such as Warfarin, but newer oral Anti-Coagulants have been gaining popularity due to their ease of use and fewer side effects. This trend is expected to continue in the coming years.

Local special circumstances: Burundi has a high incidence of cardiovascular diseases, which has been driving the demand for Anti-Coagulants. The country has a relatively low level of healthcare infrastructure, which has led to a limited availability of medical treatments. This has resulted in a higher demand for Anti-Coagulants as a treatment option for cardiovascular diseases.

Underlying macroeconomic factors: Burundi is one of the poorest countries in the world, with a high level of poverty and a low level of economic development. The healthcare system in Burundi is underfunded and lacks the necessary resources to provide adequate medical care. As a result, the demand for Anti-Coagulants has been driven by the private healthcare sector, which has been growing in recent years. The government has been taking steps to improve the healthcare system, which is expected to lead to an increase in the availability of medical treatments, including Anti-Coagulants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.